Optimizerx (OPRX) Stock
Digital healthcare platform connecting pharmaceutical companies and health systems. Here's the price, business snapshot, and what's worth knowing about Optimizerx in July 2026.
OptimizeRx Corporation (ticker OPRX) is a healthcare technology company that focuses on digital patient engagement and prescription access at the point of care. Its platform connects pharmaceutical companies, clinicians and health systems to deliver targeted messages, patient savings offers and clinical information during prescribing workflows. With a market capitalisation of about $368.33m, OptimizeRx sits in the small‑cap segment where growth potential can be meaningful but volatility is common. Revenue drivers typically include platform fees, campaign services and data-driven solutions; prospective investors should consult the latest financial reports for current details. Key opportunities include wider adoption of electronic prescribing and partnership expansion, while risks include competition, regulatory changes, reimbursement dynamics and execution challenges. This is general educational information only, not personal financial advice — investors should perform their own research and consider seeking professional guidance. Past performance is not a reliable indicator of future returns and capital is at risk.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying OptimizeRx stock as it has potential to rise to $12.36.
Financial Health
OptimizeRx Corporation is performing well with strong revenue and profit margins, indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AUTOMATIC DATA PROCESSING INC
Provides business process outsourcing and technology services.
AIRBNB INC
Airbnb is a hospitality company that provides a platform for users to list, discover, and book accommodations and experiences around the world.
ADOBE INC
Develops software and cloud-based solutions for digital media and digital marketing.
Baskets Featuring OPRX
Oral Obesity Treatments: Investment Theme Explained
Novo Nordisk has launched the first oral GLP-1 weight loss medication, Wegovy, representing a major evolution in the obesity treatment landscape. This shift from injections to pills creates an investment opportunity in pharmaceutical innovators and the digital health companies enabling broad access.
Published: 6 January 2026
Explore BasketClinical Trial Tech: Growth vs Competition Risks
Thermo Fisher's multi-billion dollar acquisition of Clario, a clinical trial data company, signals a major industry shift towards digital solutions. This creates a compelling investment case for companies specializing in the software and data analytics that power modern drug development.
Published: 29 October 2025
Explore BasketSupply Chain Stocks: May Tariff Impacts Drive Growth?
The continued contraction of the U.S. manufacturing sector, heavily influenced by tariff wars, underscores the challenges facing domestic producers. This environment may create investment opportunities in companies that provide solutions for supply chain optimization and cost reduction.
Published: 3 September 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: 19 August 2025
Explore BasketThe Corporate Efficiency Drive
Starbucks announced a modest, standardized raise for its salaried employees as part of a broader cost-control and operational efficiency strategy. This move signals a potential investment opportunity in companies providing business optimization and cost-saving solutions to large corporations.
Published: 19 August 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: 4 August 2025
Explore BasketDigital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Published: 17 June 2025
Explore BasketDigital Therapeutics
Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.
Published: 17 June 2025
Explore BasketBio-Hacking Portfolio
Discover companies at the cutting edge of human optimization, where biology meets technology. These carefully selected stocks represent innovators developing data-driven solutions for personalized health, enhanced performance, and extended longevity.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Point-of-care reach
The platform delivers messages and savings at prescribing moments, which can influence uptake — though adoption and regulation can affect outcomes.
Partner network growth
Engagement with pharma and health systems could scale campaign revenue, but competition and integration complexity are important considerations.
Execution and funding
As a small‑cap technology business, progress relies on execution and prudent finances; volatility and potential funding needs are risks to watch.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
